Bora Pharma Expands Midwest Site Following Upsher-Smith Split Finalization
Bora Pharmaceuticals Unveils Multi-Year Expansion of Maple Grove Site as U.S. Growth Strategy Advances Post-Upsher-Smith Split Bora Pharmaceuticals Co., Ltd. (TWSE: 6472), a leading global contract development and manufacturing organization…
Promega and Aobious Settle Patent Infringement Dispute
Promega and Aobious Reach Comprehensive Settlement in Patent Infringement Lawsuit Over Bioluminescent Technology Promega Corporation and Aobious Inc. have officially concluded a contentious legal battle over bioluminescent reagent patents, reaching…
New Study Reveals Improved Outcomes for Hospitalized Surgical Patients
U.S. Hospitals Achieve Significant Gains in Surgical Patient Outcomes Since 2019, AHA and Vizient Report Shows In a compelling new report released jointly by the American Hospital Association (AHA) and…
Kashiv BioSciences and MS Pharma Partner on MENA Rights for XOLAIR® Biosimilar ADL-018
Kashiv BioSciences and MS Pharma Forge Strategic Alliance to Bring XOLAIR® Biosimilar ADL-018 to MENA Region Kashiv BioSciences, LLC, a U.S.-based biopharmaceutical company specializing in complex generics and biosimilars, and…
Navitus and Costco Pharmacy Join Forces to Promote Drug Price Transparency
Navitus and Costco Pharmacy Partner to Transform Drug Pricing Transparency with Cost-Plus Model Launching in 2026 In a bold move aimed at reshaping the landscape of prescription drug pricing in…
Charles River Associates Broadens Reach with Expansion of Life Sciences Practice
Charles River Associates Expands Life Sciences Practice with Appointment of Two Seasoned Industry Leaders Charles River Associates (NASDAQ: CRAI), a globally recognized leader in economic, financial, and management consulting, has…
Genmab Names Dr. Katja Nielsen as New General Manager for Germany
Genmab Appoints Dr. Katja Nielsen as General Manager for Germany, Strengthening European Commercial Expansion Genmab A/S (Nasdaq Copenhagen: GMAB), a global biotechnology leader in antibody-based medicines for cancer and other…
Roche’s Susvimo Preserves Vision for 5 Years with Twice-Yearly Dosing in nAMD
Roche’s Susvimo Shows Durable Vision Preservation Over Five Years with Twice-Yearly Treatment in Neovascular AMD Roche has released compelling new long-term data highlighting the extended efficacy, safety, and durability of…
Spine BioPharma Reports Phase 3 Topline Results for SB-01 in Chronic Low Back Pain
Spine BioPharma Releases Phase 3 Data for SB-01 in Chronic Low Back Pain: Trial Misses Primary Endpoint Amid Strong Safety and Subgroup Efficacy Signals Spine BioPharma, Inc., a clinical-stage biopharmaceutical…
United Therapeutics Launches $1 Billion Accelerated Stock Buyback Program
United Therapeutics Launches $1 Billion Accelerated Share Repurchase Initiative, Underscoring Confidence in Long-Term Growth and Shareholder Value In a bold affirmation of its robust financial health, strategic vision, and shareholder-centric…
Arrowhead’s Subsidiary Visirna Sells China Rights for Plozasiran to Sanofi
Arrowhead’s Subsidiary Visirna Transfers Greater China Rights to Plozasiran to Sanofi in Strategic $395 Million Deal Amid Regulatory Milestone in Hypertriglyceridemia In a move poised to reshape the therapeutic landscape…
EC Approves CAR-T Therapy Using AGC Biologics’ Lentiviral Vectors
European Commission Greenlights AUCATZYL®: AGC Biologics Marks 10th Regulatory Approval with Autolus’ CAR-T Therapy AGC Biologics, a global contract development and manufacturing organization (CDMO) specializing in biologics and advanced therapies,…